Market closed

Glaukos/$GKOS

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Glaukos

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Ticker

$GKOS

Sector

Health Care

Trading on

NYSE

Industry

Health Care Equipment & Supplies

Headquarters

Aliso Viejo, United States

Employees

907

Website

www.glaukos.com

Glaukos Metrics

BasicAdvanced

$8.4B

-

-$2.93

1.03 -

Price and volume

Market cap

$8.4B

Beta

1.03

52-week high

$161.13

52-week low

$83.90

Average daily volume

605K

Financial strength

Current ratio

5.542

Quick ratio

4.448

Long term debt to equity

23.504

Total debt to equity

23.897

Interest coverage (TTM)

-9.76%

Management effectiveness

Return on assets (TTM)

-7.74%

Return on equity (TTM)

-26.10%

Valuation

Price to revenue (TTM)

21.525

Price to book

12.52

Price to tangible book (TTM)

25.13

Price to free cash flow (TTM)

-95.439

Growth

Revenue change (TTM)

18.70%

Earnings per share change (TTM)

8.83%

3-year revenue growth (CAGR)

7.02%

3-year earnings per share growth (CAGR)

51.95%

What the Analysts think about Glaukos

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Glaukos stock.

Glaukos Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Glaukos Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Glaukos News

AllArticlesVideos

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Benzinga·2 weeks ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Seeking Alpha·4 weeks ago

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Benzinga·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GKOS

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Glaukos stock?

Glaukos (GKOS) has a market cap of $8.4B as of January 15, 2025.

What is the P/E ratio for Glaukos stock?

The price to earnings (P/E) ratio for Glaukos (GKOS) stock is 0 as of January 15, 2025.

Does Glaukos stock pay dividends?

No, Glaukos (GKOS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Glaukos dividend payment date?

Glaukos (GKOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Glaukos?

Glaukos (GKOS) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.